Advances in Biology of Acute Lymphoblastic Leukemia (ALL) and Therapeutic Implications

Overview

Journal Am J Blood Res

Specialty Hematology

Date 2019 Jan 31

PMID 30697448

Citations 24

Authors

Mahsa Mohseni

Hasan Uludag

Joseph M Brandwein

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and also occurs in adults. Although the outcomes of multi-agent chemotherapy regimens have greatly improved, high toxicity and relapses in many patients necessitate the development of novel therapeutic approaches. Advances in molecular profiling and cytogenetics have identified a broad range of genetic abnormalities, including gene mutations, chromosome translocations and aneuploidy, which has provided a more comprehensive understanding of the biology and pathogenesis of ALL. This understanding has also led to new targeted therapeutic approaches, including the use of selective small molecule inhibitors, nucleic acid-based therapies and immune-based therapies mediated by specific monoclonal antibodies and cellular immunotherapy, which are poised to revolutionize the treatment of various ALL subtypes. The main focus of this review is to highlight the latest advances in ALL biology, including the identification of prognostic factors and putative therapeutic targets. We also review the current status of, and ongoing progress in, the development of targeted therapies for ALL.

Citing Articles

Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers.

Ahmed N, Mohamed M, Awad S, El-Hameed R, El-Tawab N, Gaballah M J Enzyme Inhib Med Chem. 2024; 39(1):2304625.

PMID: 38348824 PMC: 10866072. DOI: 10.1080/14756366.2024.2304625.

Clinical and prognostic significance of CD27 and CD44 expression patterns in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.

Abobakr A, Osman R, Kamal M, Abdelhameed S, Ismail H, Kamel M Hematol Transfus Cell Ther. 2023; 46 Suppl 6:S27-S35.

PMID: 38065726 PMC: 11726023. DOI: 10.1016/j.htct.2023.10.003.

Clinically relevant core genes for hematologic malignancies in clinical NGS panel testing.

Song J Blood Res. 2023; 58(4):224-228.

PMID: 37926559 PMC: 10758630. DOI: 10.5045/br.2023.2023196.

Pre- and Postnatal Exposures to Tobacco Smoking and Survival of Childhood Acute Lymphoblastic and Myeloid Leukemias in California, United States.

Metayer C, Morimoto L, Kang A, Sanchez Alvarez J, Winestone L Cancer Epidemiol Biomarkers Prev. 2023; 33(1):117-125.

PMID: 37921440 PMC: 11008006. DOI: 10.1158/1055-9965.EPI-23-0801.

Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies.

Munir F, He J, Connors J, Garcia M, Gibson A, McCall D Transl Pediatr. 2023; 12(3):487-502.

PMID: 37035397 PMC: 10080491. DOI: 10.21037/tp-22-656.

References

Roman-Gomez J, Agirre X, Jimenez-Velasco A, Arqueros V, Vilas-Zornoza A, Rodriguez-Otero P . Epigenetic regulation of microRNAs in acute lymphoblastic leukemia. J Clin Oncol. 2009; 27(8):1316-22. DOI: 10.1200/JCO.2008.19.3441. View

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S . Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. 2017; 31(5):1087-1095. DOI: 10.1038/leu.2017.39. View

Uckun F, Zheng Y, Cetkovic-Cvrlje M, Vassilev A, Lisowski E, Waurzyniak B . In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase. Clin Cancer Res. 2002; 8(5):1224-33. View

Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K . NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2008; 113(17):3918-24. DOI: 10.1182/blood-2008-10-184069. View

Maude S, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A . Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015; 125(11):1759-67. PMC: 4357583. DOI: 10.1182/blood-2014-06-580480. View

Savino A, Sarno J, Trentin L, Vieri M, Fazio G, Bardini M . The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Leukemia. 2017; 31(11):2365-2375. DOI: 10.1038/leu.2017.93. View

Rousselot P, Coude M, Gokbuget N, Passerini C, Hayette S, Cayuela J . Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016; 128(6):774-82. PMC: 5085255. DOI: 10.1182/blood-2016-02-700153. View

Grandori C, Cowley S, James L, Eisenman R . The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000; 16:653-99. DOI: 10.1146/annurev.cellbio.16.1.653. View

Ravandi F, Jorgensen J, Thomas D, OBrien S, Garris R, Faderl S . Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013; 122(7):1214-21. PMC: 3976223. DOI: 10.1182/blood-2012-11-466482. View

10.

Wei G, Wang J, Huang H, Zhao Y . Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol. 2017; 10(1):150. PMC: 5563021. DOI: 10.1186/s13045-017-0516-x. View

11.

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman M . Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat Genet. 2016; 48(12):1481-1489. PMC: 5144107. DOI: 10.1038/ng.3691. View

12.

Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S . Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004; 10(10):3371-6. DOI: 10.1158/1078-0432.CCR-03-0508. View

13.

Wells J, Jain N, Konopleva M . Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype. Clin Adv Hematol Oncol. 2017; 15(7):554-561. View

14.

Neri L, Cani A, Martelli A, Simioni C, Junghanss C, Tabellini G . Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 2013; 28(4):739-48. DOI: 10.1038/leu.2013.226. View

15.

Bai X, Moles R, Chaib-Mezrag H, Nicot C . Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells. J Hematol Oncol. 2015; 8:117. PMC: 4619390. DOI: 10.1186/s13045-015-0217-2. View

16.

Weng A, Ferrando A, Lee W, Morris 4th J, Silverman L, Sanchez-Irizarry C . Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004; 306(5694):269-71. DOI: 10.1126/science.1102160. View

17.

Daub H, Specht K, Ullrich A . Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov. 2004; 3(12):1001-10. DOI: 10.1038/nrd1579. View

18.

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

19.

Barisone G, Satake N, Lewis C, Duong C, Chen C, Lam K . Loss of MXD3 induces apoptosis of Reh human precursor B acute lymphoblastic leukemia cells. Blood Cells Mol Dis. 2015; 54(4):329-35. PMC: 4387021. DOI: 10.1016/j.bcmd.2014.12.002. View

20.

Ribera J, Oriol A, Morgades M, Montesinos P, Sarra J, Gonzalez-Campos J . Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the.... J Clin Oncol. 2014; 32(15):1595-604. DOI: 10.1200/JCO.2013.52.2425. View